Antiviral therapy improves survival rates for kidney transplant recipients with hepatitis B or C
In a new study in the Journal of Hepatology, researchers report favorable 10-year survival rates for patients with HBV and/or HCV treated with antiviral agents and advise that antiviral therapy should be systematically offered to all HBV and HCV patients in line with international recommendations.